ESMO 2020 — Is there a role for trabectedin in ovarian cancer progressing after platinum treatment?


  • Cristina Ferrario — Agenzia Zoe
  • Oncology Conference reports
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Platinum-based regimens remain standard-of-care (SoC) in patients with recurrent ovarian cancer (ROC) progressing after a platinum-free interval (TFIp) of 6-12 months.
  • Trabectedin/pegylated liposomal doxorubicin (PLD) could play a role in patients in need of longer recovery time from platinum-specific toxicities.

Why this matters?

  • Results of clinical and preclinical studies suggest that trabectedin could improve the efficacy of re-treatment with platinum in ROC.

Study design

  • Phase 3 study (INOVATYON): 617 patients with ROC and TFIp of 6-12 months enrolled from 117 European sites.
  • Patients randomized to trabectedin (1.1 mg/m2) and PLD (30 mg/m2) or carboplatin (AUC 5) and PLD (30 mg/m2) followed, at progression, by platinum re-challenge (trabectedin group) or therapy at investigator discretion (carboplatin group).
  • Primary endpoint: overall survival (OS).
  • Secondary aims: progression-free survival (PFS), PFS from subsequent therapy (PFS-ST), safety, quality of life (QoL; QLQ-C30 and QLQ-OV28).
  • Funding: PharmaMar.

Key results

  • Median TFIp: 8.4 months.
  • Interruption of treatment before the sixth cycle: 28.3% and 45.6% of patients in carboplatin and trabectedin arm, respectively.
  • Median OS: 21.5 months with trabectedin and 21.3 months with carboplatin (HR 1.10, 95% CI 0.92-1.32, P=.284).
  • Median PFS: 7.5 and 9.0 months in trabectedin and carboplatin arm (HR 1.26, 95% CI 1.07-1.49, P=.005).
  • PFS after ST was in favour of trabectedin (HR 0.80, 95% CI 0.65-0.98, P=.028).
  • QoL and safety results favoured carboplatin/PLD.

Expert commentary

“This study deal with an old question in gynaecological oncology, namely if prolonging platinum-free interval may enhance the efficacy of platinum re-treatment. The question is now solved: the platinum remains the standard-of-care in this population”. Andreas du Bois, Professor of gynaecologic oncology at Kliniken Essen Mitte (Essen) and AGO Study group (Germany).

Follow all ESMO 2020 coverage on   Univadis .